- Home
- PTOR vs ABEO Comparison
PTOR vs ABEO Comparison
Compare PTOR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTOR | ABEO |
|---|---|---|
| Founded | 2025 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.9M | 399.5M |
| IPO Year | 2026 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PTOR | ABEO |
|---|---|---|
| Price | $9.99 | $5.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 18.0K | ★ 1.5M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.78 | $4.00 |
| 52 Week High | $10.04 | $7.65 |
Technical Indicators
Market Signals| Indicator | PTOR | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 60.62 | 34.08 |
| Support Level | $9.92 | $4.91 |
| Resistance Level | $10.02 | $5.52 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 100.00 | 19.31 |
Price Performance
Historical ComparisonAbout PTOR Praetorian Acquisition Corp. Class A Ordinary Shares
Praetorian Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.